抗高血压治疗后肌酐水平升高对患者心血管事件发生率的影响研究

胡芳英; 方红薇; 林萍; 张秋实; 马静; 陈月芳

doi:10.16766/j.cnki.issn.1674-4152.002544

抗高血压治疗后肌酐水平升高对患者心血管事件发生率的影响研究

doi: 10.16766/j.cnki.issn.1674-4152.002544

1.
杭州市第三人民医院老年医学科，浙江杭州 310009
2.
杭州市第三人民医院心内科，浙江杭州 310009
3.
杭州市第三人民医院皮肤科，浙江杭州 310009

基金项目:

浙江省医药卫生计划B类项目 2020KY724

详细信息

通讯作者:
方红薇, E-mail: fanghongwei1974@126.com

中图分类号: R544.1
计量
- 文章访问数: 135
- HTML全文浏览量: 56
- PDF下载量: 4
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-01
- 网络出版日期: 2022-09-23

Study on the effect of increased creatinine level after antihypertensive treatment on the risk of cardiovascular events in patients

1.
Department of Geriatrics, Hangzhou Third People's Hospital, Hangzhou, Zhejiang 310009, China

摘要

摘要: 目的抗高血压治疗中肾素-血管紧张素抑制剂伴随的肾功能下降与心血管疾病的发生率升高相关，但其他降压药相关的研究仍较少。本文旨在探究采用一线抗高血压药物治疗后血浆肌酐升高对相关心血管事件发生率的影响。方法纳入2015年10月—2020年6月至杭州市第三人民医院就诊的高血压患者182例，男性96例，女性86例，年龄为(60.5±6.4)岁。所有患者在此时间段内接受肾素-血管紧张素抑制剂、钙通道阻滞剂或噻嗪类抗高血压药物治疗。通过治疗前基线肌酐水平及最近一次(≤90 d)的测量值计算血浆肌酐升高的百分比，探究6个月心血管事件(缺血性心肌病、心力衰竭或和脑卒中)的发生率与肌酐升高的相关性。结果按照肌酐水平进行分组，分别为A组(0%~9%，79例)、B组(10%~19%，40例)、C组(20%~29%，27例)、D组(30%~39%，20例)、E组(>40%，16例)，43.4%(79/182)的患者肌酐升高水平在0%~9%。在随访6个月时间内总计发生心血管事件6例(3.3%)，无死亡患者。肌酐升高0%~9%和30%~39%相应的6个月心血管事件发生率分别为0%和1.1%。总随访时间为3.1(1.8, 5.8)年，整体心血管事件发生率为8.2%(15/182)，D组和E组的发生率显著高于其他组(P＜0.001)。较高的年龄、肾功能降低和相应的抗高血压药物均与心血管事件的发生率密切相关。结论初级预防中开始一线抗高血压治疗的患者血浆肌酐水平升高30%以上与近期(6个月)及远期(3年)的心血管事件发生率升高相关。
- 抗高血压治疗 /
- 高血压 /
- 肌酐 /
- 心血管事件
Abstract: Objective Decreased renal function associated with renin-angiotensin inhibitors in antihypertensive therapy is associated with an increased risk of cardiovascular disease. However, few studies on other antihypertensive drugs are available. This study aimed to investigate the incidence of cardiovascular events associated with elevated plasma creatinine following first-line antihypertensive medication. Methods A total of 182 patients with hypertension who visited Hangzhou Third People's Hospital from October 2015 to June 2020 were enrolled, including 96 males and 86 females, aged (60.5±6.4) years. All patients received renin-angiotensin inhibitors, calcium channel blockers or thiazide antihypertensives during this time period. The correlation between the incidence of 6-month cardiovascular events (ischemic cardiomyopathy, heart failure or stroke) and elevated creatinine was explored. Results In accordance with creatinine level, the patients were divided into group A (0%-9%, 79 cases), group B (10%-19%, 40 cases), group C (20%-29%, 27 cases), group D (30%-39%, 20 cases) and group E (>40%, 16 cases). Amongst them, 43.4% (79/182) of patients had an elevated creatinine level of 0%-9%. Six cardiovascular events (3.3%) occurred during the 6-month follow-up period, and no patient died. The creatinine elevations of 0%-9% and 30%-39% corresponded to 6-month cardiovascular event rates of 0.6% and 3.4%, respectively. The total follow-up time was 3.1 (1.8, 5.8) years, the overall incidence of cardiovascular events was 8.2% (15/182) and the incidence in groups D and E was significantly higher than that in other groups (P < 0.001). Higher age and reduced renal function were strongly associated with increased odds of cardiovascular events but not with type of antihypertensive medication. Conclusion A greater than 30% increase in plasma creatinine levels in patients starting first-line antihypertensive therapy in primary prevention is associated with increased short-term (6 months) and long-term (3 years) incidence of cardiovascular events.
- Antihypertensive therapy /
- Hypertension /
- Creatinine /
- Cardiovascular events

HTML全文

图 1 各组高血压患者第2次肌酐测量后3年心血管事件累积发生率

Figure 1. Cumulative incidence of cardiovascular events 3 years after the second creatinine measurement in hypertensive patients in each group

下载: 全尺寸图片幻灯片

表 1 各组高血压患者的基本特征比较[例(%)]

Table 1. Comparison of basic characteristics of hypertensive patients in each group [cases(%)]

组别	例数	性别		eGFR≥60 mL/(min·1.73 m²)		ACR			抗高血压药物
组别	例数	男性	女性	eGFR≥60 mL/(min·1.73 m²)		＜30	30~300	＞300	ARBs	CCB	噻嗪类
整体	182	96(52.7)	86(47.3)	175(96.2)		125(68.7)	40(22.0)	17(9.3)	130(71.4)	22(12.1)	30(16.5)
A组	79	41(51.9)	38(48.1)	76(96.2)		55(69.6)	17(21.5)	7(8.8)	62(78.5)	9(11.4)	8(10.1)
B组	40	21(52.5)	19(47.5)	39(97.5)		28(70.0)	8(20.0)	4(10.0)	30(75.0)	4(10.0)	6(15.0)
C组	27	14(51.9)	13(48.1)	26(96.3)		18(66.7)	6(22.2)	3(11.1)	17(63.0)	4(14.8)	6(22.2)
D组	20	11(55.0)	9(45.0)	19(98.5)		13(65.0)	5(25.0)	2(10.0)	12(60.0)	3(15.0)	5(25.0)
E组	16	9(56.3)	7(43.7)	15(93.8)		11(68.8)	4(25.0)	1(6.3)	9(56.3)	2(12.5)	5(31.3)
统计量		0.558^a		1.151^a		15.332^b			3.544^a
P值		0.071		0.222		0.206			＜0.001

组别	例数	糖尿病		HbA1c					总胆固醇		COPD
组别	例数	糖尿病		正常水平	高于正常水平	显著高水平	低水平		＜5 mmol/L	≥5 mmol/L	COPD
整体	182	27(14.8)		114(62.6)	35(19.2)	20(11.0)	13(7.1)		64(35.2)	118(64.8)	8(4.4)
A组	79	10(12.7)		50(63.3)	15(19.0)	8(10.1)	6(7.6)		28(35.4)	51(64.6)	3(3.8)
B组	40	6(15.0)		24(60.0)	8(20.0)	5(12.5)	3(7.5)		14(35.0)	26(65.0)	2(5.0)
C组	27	4(14.8)		17(63.0)	5(18.5)	3(11.1)	2(7.4)		9(33.3)	18(66.7)	1(3.7)
D组	20	4(20.0)		13(65.0)	4(20.0)	2(10.0)	1(5.0)		7(35.0)	13(65.0)	1(5.0)
E组	16	3(18.8)		10(62.5)	3(18.8)	2(12.5)	1(6.3)		6(37.5)	10(62.5)	1(6.3)
统计量		0.281^a		20.357^b					2.882^a		0.551^a
P值		0.381		＜0.001					0.188		0.174
注：^a为χ²值，^b为H值。

下载: 导出CSV

表 2 各组高血压患者6个月心血管事件发生率比较(%)

Table 2. Comparison of 6-month cardiovascular events in patients with hypertension in each group(%)

组别	例数	性别		年龄(岁)			eGFR[mL/(min·1.73 m²)]		抗高血压药物
组别	例数	男性	女性	18~49	50~79	≥80	＜60	≥60	CCB	ARBs	噻嗪类
A组	79	1.4	1.0	0.6	1.3	2.1	4.0	1.3	1.4	1.3	1.4
B组	40	1.7	1.2	0.8	1.8	2.8	5.0	1.9	1.8	1.6	1.7
C组	27	1.5	1.1	0.5	1.5	2.4	4.3	1.5	1.6	1.5	1.6
D组	20	3.5	2.9	1.3	3.8	6.1	10.5	3.7	4.0	3.6	3.2
E组	16	4.6	3.0	1.4	4.5	7.1	12.5	4.6	5.0	4.5	4.3
统计量		3.215^a		3.250^b			6.446^a		4.445^a
P值		＜0.001		＜0.001			＜0.001		＜0.001
注：^a为χ²值，^b为H值。

下载: 导出CSV

参考文献(20)

[1]	BAKRIS G L, AGARWAL R. Creatinine bump following antihypertensive therapy[J]. Hypertension, 2018, 72(6): 1274-1276. doi: 10.1161/HYPERTENSIONAHA.118.12051
[2]	蒋小菊, 赵印平, 刘卫华, 等. 高血压患者血管病变及心脏重构与尿微量白蛋白/肌酐关系的研究[J]. 中国社区医师, 2018, 34(15): 132-133, 135. doi: 10.3969/j.issn.1007-614x.2018.15.082 JIANG X J, ZHAO Y P, LIU WH, et al. Study on the relationship between vascular disease and cardiac remodeling and urinary microalbumin/creatinine in patients with hypertension[J]. Chinese Community Physician, 2018, 34(15): 132-133, 135. doi: 10.3969/j.issn.1007-614x.2018.15.082
[3]	PALMER S C, RUOSPO M, TEIXEIRA-PINTO A, et al. The validity of drug effects on proteinuria, albuminuria, serum creatinine, and estimated GFR as surrogate end points for ESKD: A systematic review[J]. Am J Kidney Dis, 2018, 72(6): 779-789. doi: 10.1053/j.ajkd.2018.06.011
[4]	卢湘鸿, 李翔, 张军. 血浆内皮素-1水平及晨尿白蛋白/肌酐比值与高血压及血压变异的相关性[J]. 临床医药文献电子杂志, 2018, 5(5): 15-16. doi: 10.3877/j.issn.2095-8242.2018.05.011 LU X H, LI X, ZHANG J. Correlation of plasma endothelin-1 level and morning urine albumin/creatinine ratio with hypertension and blood pressure variability[J]. Electronic Journal of Clinical Medicine, 2018, 5(5): 15-16. doi: 10.3877/j.issn.2095-8242.2018.05.011
[5]	王胜煌. 《ISH2020国际高血压实践指南》解析与宁波实践分享[J]. 中华医学信息导报, 2020, 35(13): 17. doi: 10.3760/cma.j.issn.1000-8039.2020.13.130 WANG S H. "ISH2020 International Hypertension Practice Guidelines" Analysis and Ningbo Practice Sharing[J]. China Medical Information Herald, 2020, 35(13): 17. doi: 10.3760/cma.j.issn.1000-8039.2020.13.130
[6]	李智. 高血压并发脑出血尼卡地平治疗期间血钙和血肌酐水平的变化及意义[J]. 北方药学, 2018, 15(6): 72-73. doi: 10.3969/j.issn.1672-8351.2018.06.057 LI Z. Changes and significance of serum calcium and serum creatinine levels during nicardipine treatment with hypertension complicated with cerebral hemorrhage[J]. Northern Pharmacy, 2018, 15(6): 72-73. doi: 10.3969/j.issn.1672-8351.2018.06.057
[7]	刘张玲, 蒲然, 刘霞, 等. 胱抑素C、同型半胱氨酸、尿微量清蛋白/肌酐比值联合检测在高血压早期肾损害诊断中的价值[J]. 现代医药卫生, 2019, 35(7): 1011-1013. doi: 10.3969/j.issn.1009-5519.2019.07.014 LIU Z L, PU R, LIU X, et al. The value of combined detection of cystatin C, homocysteine, and urine microalbumin/creatinine ratio in the diagnosis of early renal damage in hypertension[J]. Modern Medicine and Health, 2019, 35(7): 1011-1013. doi: 10.3969/j.issn.1009-5519.2019.07.014
[8]	BARZILAY J I, DAVIS B R, PRESSEL S L, et al. The effects of eGFR change on CVD, renal, and mortality outcomes in a hypertensive cohort treated with 3 different antihypertensive medications[J]. Am J Hypertens, 2018, 31(5): 609-614. doi: 10.1093/ajh/hpx223
[9]	周建妹, 陈进, 邓冰莹, 等. 高血压患者血清同型半胱氨酸水平与肌酐、尿酸、甲状旁腺激素的关系[J]. 心脑血管病防治, 2018, 18(5): 394-395, 398. doi: 10.3969/j.issn.1009-816x.2018.05.012 ZHOU J M, CHEN J, DENG B Y, et al. The relationship between serum homocysteine levels and creatinine, uric acid, and parathyroid hormone in patients with hypertension[J]. Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, 2018, 18(5): 394-395, 398. doi: 10.3969/j.issn.1009-816x.2018.05.012
[10]	DAMMAN K, GORI M, CLAGGETT B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure[J]. JACC Heart Fail, 2018, 6(6): 489-498. doi: 10.1016/j.jchf.2018.02.004
[11]	PARVANOVA A, TRILLINI M, PODESTA M A, et al. Blood pressure and metabolic effects of acetyl-l-carnitine in type 2 diabetes: DIABASI randomized controlled trial[J]. J Endocr Soc, 2018, 2(5): 420-436. doi: 10.1210/js.2017-00426
[12]	李志强, 傅咏华, 王春燕, 等. 联合多项自检参数对慢性心力衰竭患者管理的作用[J]. 中华全科医学, 2018, 16(7): 1128-1132. doi: 10.16766/j.cnki.issn.1674-4152.000311 LI Z Q, FU Y H, WANG C Y, et al. Effect of combined multiple self-check parameters on management of patients with chronic heart failure[J]. Chinese Journal of General Practice, 2018, 16(7): 1128-1132. doi: 10.16766/j.cnki.issn.1674-4152.000311
[13]	KIANBAKHT S, HASHEM-DABAGHIAN F. Antihypertensive efficacy and safety of Vaccinium arctostaphylos berry extract in overweight/obese hypertensive patients: A randomized, double-blind and placebo-controlled clinical trial[J]. Complement Ther Med, 2019, 44: 296-300. doi: 10.1016/j.ctim.2019.05.010
[14]	张丽娜, 杨苗苗, 王雁良, 等. 尿白蛋白/肌酐比值与原发性高血压患者临床特征的相关性分析[J]. 中华实用诊断与治疗杂志, 2019, 33(8): 816-818. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD201908027.htm ZHANG L N, YANG M M, WANG Y L, et al. Correlation between urinary albumin/creatinine ratio and clinical characteristics of primary hypertension[J]. Journal of Chinese Practical Diagnosis and Therapy, 2019, 33(8): 816-818. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD201908027.htm
[15]	张红玉, 谢席胜, 冯胜刚, 等. 慢性肾脏病高血压患者夜间高血压患病率及影响因素[J]. 西部医学, 2020, 32(1): 125-129. doi: 10.3969/j.issn.1672-3511.2020.01.029 ZHANG H Y, XIE X S, FENG S G, et al. Prevalence and influencing factors of night time hypertension in patients with chronic kidney disease and hypertension[J]. Medical Journal of West China, 2020, 32(1): 125-129. doi: 10.3969/j.issn.1672-3511.2020.01.029
[16]	OHKUMA T, JUN M, RODGERS A, et al. Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus[J]. Hypertension, 2019, 73(1): 84-91. doi: 10.1161/HYPERTENSIONAHA.118.12060
[17]	FUJIWARA T, YANO Y, HOSHIDE S, et al. Association between change in central nocturnal blood pressure and urine albumin-creatinine ratio by a valsartan/amlodipine combination: A CPET study[J]. Am J Hypertens, 2018, 31(9): 995-1001. doi: 10.1093/ajh/hpy078
[18]	吕良冬, 宋瑞芳, 王永光, 等. 血肌酐正常冠心病患者危险因素分析及血清胱抑素C检测意义[J]. 中华全科医学, 2017, 15(9): 1626-1628. doi: 10.16766/j.cnki.issn.1674-4152.2017.09.052 LV L D, SONG R F, WANG Y G, et al. Analysis of risk factors and significance of serum cystatin C detection in patients with coronary heart disease with normal serum creatinine[J]. Chinese Journal of General Practice, 2017, 15(9): 1626-1628. doi: 10.16766/j.cnki.issn.1674-4152.2017.09.052
[19]	COLLARD D, BROUWER T F, PETERS R J G, et al. Creatinine rises during blood pressure therapy and the risk of adverse clinical outcomes in patients with type 2 diabetes mellitus[J]. Hypertension, 2018, 72(6): 1337-1344. doi: 10.1161/HYPERTENSIONAHA.118.11944
[20]	余信强, 张苏川. 原发性高血压病人早期肾损伤影响因素的临床研究[J]. 蚌埠医学院学报, 2019, 44(2): 167-170. https://www.cnki.com.cn/Article/CJFDTOTAL-BANG201902009.htm YU X Q, ZHANG S C. Study on the influencing factor of early renal damage in patients with primary hypertension[J]. Journal of Bengbu Medical College, 2019, 44(2): 167-170. https://www.cnki.com.cn/Article/CJFDTOTAL-BANG201902009.htm